Enliven Therapeutics Inc Share Price Today: Live Updates & Key Insights

Enliven Therapeutics Inc share price today is $28.96, up -3.39%. The stock opened at $29.93 against the previous close of $30.05, with an intraday high of $30.02 and low of $28.655.

Enliven Therapeutics Inc Share Price Chart

Enliven Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Enliven Therapeutics Inc Share Price Performance

$28.96 -0.0339(-3.39%) ELVN at 23 Mar 2026 12:52 PM Biotechnology
Lowest Today 28.655
Highest Today 30.02
Today’s Open 29.93
Prev. Close 30.05
52 Week High 31.76
52 Week Low 13.30
Day’s Range: Low 28.655 High 30.02
52-Week Range: Low 13.30 High 31.76
1 day return -
1 Week return +5.62
1 month return +5.24
3 month return +61.29
6 month return +44.88
1 year return +28.64
3 year return +31.75
5 year return -28.27
10 year return -

Enliven Therapeutics Inc Institutional Holdings

Enliven Therapeutics Inc Market Status

Strong Buy: 7

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Enliven Therapeutics Inc Fundamentals

Market Cap 1736.01 M

PB Ratio 3.9099

PE Ratio 0.0

Enterprise Value 1273.78 M

Total Assets 476.17 M

Volume 862701

Enliven Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:-297000 -0.3M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-71584000 -71.6M, FY22:-37750000 -37.8M, FY21:-24718000 -24.7M, FY20:-18935000 -18.9M, FY19:-23463000 -23.5M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-81000 -0.1M, Q1/2025:-74000 -0.1M, Q3/2024:null 0.0M, Q2/2024:-79000 -0.1M

Quarterly Net worth Q3/2025:-20148000 -20.1M, Q2/2025:-25335000 -25.3M, Q1/2025:-28544000 -28.5M, Q3/2024:-23156000 -23.2M, Q2/2024:-19950000 -20.0M

About Enliven Therapeutics Inc & investment objective

Company Information Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Organisation Biotechnology

Employees 60

Industry Biotechnology

CEO Mr. Richard A. Fair

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Enliven Therapeutics Inc FAQs

What is the share price of Enliven Therapeutics Inc today?

The current share price of Enliven Therapeutics Inc is $28.96.

Can I buy Enliven Therapeutics Inc shares in India?

Yes, Indian investors can buy Enliven Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Enliven Therapeutics Inc shares in India?

You can easily invest in Enliven Therapeutics Inc shares from India by:

Can I buy fractional shares of Enliven Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Enliven Therapeutics Inc?

Enliven Therapeutics Inc has a market cap of $1736.01 M.

In which sector does Enliven Therapeutics Inc belong?

Enliven Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Enliven Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Enliven Therapeutics Inc?

The PE ratio of Enliven Therapeutics Inc is N/A and the PB ratio is 3.91.